Stocks and InvestingStocks and Investing
Thu, March 10, 2022
Wed, March 9, 2022
Tue, March 8, 2022
Mon, March 7, 2022

Salveen Richter Maintained (ACAD) at Hold with Decreased Target to $24 on, Mar 7th, 2022


Published on 2024-10-27 19:58:36 - WOPRAI, Salveen Richter
  Print publication without navigation


Salveen Richter of Goldman Sachs, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Decreased Target from $27 to $24 on, Mar 7th, 2022.

Salveen has made no other calls on ACAD in the last 4 months.



There are 10 other peers that have a rating on ACAD. Out of the 10 peers that are also analyzing ACAD, 6 agree with Salveen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Vamil Divan of "Mizuho" Maintained at Hold with Decreased Target to $28 on, Thursday, March 3rd, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $31 on, Tuesday, March 1st, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $30 on, Wednesday, December 22nd, 2021
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $28 on, Tuesday, December 21st, 2021
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Thursday, December 9th, 2021
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021


These are the ratings of the 4 analyists that currently disagree with Salveen


  • Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $35 on, Tuesday, March 1st, 2022
  • Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Increased Target to $36 on, Wednesday, February 9th, 2022
  • Neena Bitritto-Garg of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $30 on, Wednesday, January 5th, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Tuesday, December 21st, 2021